Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders
Engin Emrem Bestepe, Nazlı Tunali, Gökçe Elif Sarıdoğan Department of Psychiatry, Erenkoy Mental Health and Neurological Diseases Training and Research Hospital, University of Health Sciences, Istanbul, TurkeyCorrespondence: Gökçe Elif SarıdoğanDepartment of P...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/76791385ec7041bc8f35907c58c1a57f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Engin Emrem Bestepe, Nazlı Tunali, Gökçe Elif Sarıdoğan Department of Psychiatry, Erenkoy Mental Health and Neurological Diseases Training and Research Hospital, University of Health Sciences, Istanbul, TurkeyCorrespondence: Gökçe Elif SarıdoğanDepartment of Psychiatry, Erenkoy Mental Health and Neurological Diseases Training and Research Hospital, University of Health Sciences, Sinan Ercan Cad. No: 23 Kazasker, Istanbul 34736, TurkeyTel +90 532 503 27 97Email drgokcesaridogan@gmail.comBackground and Objectives: Compliance and maintenance of abstinence is a major issue in substance use disorders. Adverse effects of opioid maintenance treatments (OMT) include sexual dysfunctions. There is a vast amount of studies regarding sexual adverse effects of conventional OMTs; however, information regarding buprenorphine/naloxone (Bup/Nal) combination is limited, mostly evaluated in western populations and controversial. In this study, we aimed to assess the sexual adversities of Bup/Nal treatment in a Turkish alcohol and substance use disorder treatment center sample.Materials and Methods: We recruited 100 subjects continuing sublingual Bup/Nal combination and 35 control subjects. Subjects were evaluated via the the Golombok-Rust Inventory of Sexual Satisfaction (GRISS) for sexual dysfunction and for erectile dysfunction (ED) with the International Index of Erectile Function-5 (IIEF-5) as a comparison.Results: The mean dose of our treatment was 9.05. Overall sexual dysfunction scores were not significantly different in between groups with GRISS. ED and noncommunication scores were significantly higher in the Bup/Nal treatment group than the control group (p = 0.002, p = 0.02, respectively). Along with the increased ED scores in GRISS, IIEF-5 total scores also revealed more significant severity of the ED in the Bup/Nal group (p = 0.001).Conclusion: Buprenorphine/naloxone combination lead to a higher degree of ED severity than the non-treatment controls. Noncommunication seems to play a role as a risk factor for ED in patients with opioid use disorder. Thus, effective communication can be a key factor for sexual assertivity and disclosing the sexual adverse effects to the clinicians as well as staying in the treatment.Keywords: buprenorphine maintenance, Turkey, substance-related disorders, men, methadone |
|---|